ECCO 2024

Are all JAKies the same?

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs. Tofacitinib in UC

Primary sclerosing cholangitis – lessons from a large PSC-IBD registry

Finally here: controlled trials in surgery!

A spotlight on the PROFILE study

Cell-based therapies: The end of the story or the bright future?

Combination of different drug classes - risks and benefits

Treatment targets in 2024 - a silent revolution

Mirikizumab in CD

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Mirikizumab vs Ustekinumab

Changing the PROFILE of how we treat CD

Darvadstrocel for complex perianal fistulas and Crohn’s Disease

Mirikizumab in moderate to severe Crohn’s disease: overall assessment of the VIVID-1 trial

Tregs - a treatment for the future?

Results of the phase II PIZZICATO (ritlecitinib & brepocitinib) in Crohn's disease

PIZZICATO - new JAKies for crohn's disease

VIVID 1: Mirikizumab in Crohn's Disease

Mirikizumab in crohn's disease

VIVID 1: Comparison of mirikizumab with ustekinumab in Crohn’s disease

Mirikizumab vs Ustekinumab

Resultaten van de fase 2 PIZZICATO (ritlecitinib & brepocitinib) studie in ziekte van Crohn

PIZZICATO - neue JAKs für Morbus Crohn

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na Doença de Crohn

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC: Συνολική ανάλυση μελέτης Vivid-1

Mirikizumab bei Morbus Crohn

VTX002 (S1P-modulator) & obefazimod in ulcerative colitis

Risankizumab & guselkumab in ulcerative colitis

Long term outcome of Obefazimod in UC

The efficacy of biologics and small molecules in microscopic colitis – an ECCO Confer Cases study results

Mirikizumab in anti-TNF failures with UC

VTX-002 in patients with moderate to severe UC

Leki biologiczne i małocząsteczkowe w terapii mikroskopowych zapaleń jelit – wnioski z badania ECCO Confer Cases

Risankizumab & Guselkumab bei Colitis Ulcerosa

VTX002 (S1P-Modulator) & Obefazimod bei Colitis Ulcerosa

lange-termijns uitkomst van obefazimod in UC

VTX-002 in pazienti con colite ulcerosa da moderata a grave

Therapy in transition

Comparability examination between SB17 and Ustekimumab originator

Still a long road ahead in standards of care in IBD – the results of an E-QUALITY survey

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na temat standardów opieki w IBD

Therapie im Umbruch

Esame di comparabilità tra SP17 e ustekimumab originator

PROFILE: Biomarkers not successfull for therapy prediction

PROFILE: practice-changing results

Should we proactively treat CD-patients having small bowel lesions on capsules?

Biomarker for biological loss of response in CD?

Allogenic mesenchymal stem cells for complex fistula in CD: End of the story?

Changing treatment paradigm in CD

Early intervention in Crohn´s disease therapy

Results from the PROFILE-trial

Biomarker for biological loss of response in CD?

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der Therapieantwort

Risultati dallo studio PROFILE

Cambiano i paradigmi di trattamento nelle malattie di crohn

Injection de cellules souches mesenchimateuses allogéniques dans les fistules complexes de la maladie de Crohn: Fin de l'histoire?

Faut-il traiter les patients avec les lesions de Crohn en videocapsules?

Intervenção terapêutica precoce na doença de Crohn

Guselkumab & Golimumab have complementary effects when given together

Towards the proactive management of AS-UC responding to IB-steroids

Vers un traitement plus agressif de la colite aigüe grave cortico-sensible

Guselkumab & Golimumab ont des effets complémentaires lorqu'ils sont associés

Immunohomeostasis by regulatory CAR-T cells!?

Use of CAR-Tregs in IBD: preclinical data

Personalized treatment in IBD: reality or hype?

HD-WLE with segmental reinspection is not inferior to HD-dye-based CE in detecting colorectal neoplasia in IBD

Therapy in transition

Utilizzo di cellule CAR Tregs nelle MICI: dati preclinici

Immunohomöstase durch regulatorische CAR-T-Zellen!?

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της χρωμοενδοσκόπησης στην ανίχνευση νεοπλασίας στο παχύ έντερο στις ΙΦΝΕ

gepersonaliseerde aanpak van IBD: realiteit of hype?

Therapie im Umbruch

MIRACLE project: Avoidance of protective Ileostomy

Extended mesenterectomy is not superior to mesenteric sparing resection to prevent postoperative recurrence of CD

Randomised clinical trials finally coming to IBD surgery!

No changes to surgical techniques for ileosecal disection in CD

Colectomy and the natural history of PSC – lessons form a large PSC-IBD registry

Implication of proctocolectomy in patients affected by UC

End of the Kono-S legend!

Kolektomia a historia naturalna PSC – czy istnieje zależność?

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της διατήρησής του για την πρόληψη της μετεγχειρητικής νόσου του Crohn

La fin de la legende du Kono-S!

Implicazioni della proctocolectomia in pazienti affetti da colite ulcerosa

Los ensayos clínicos aleatorizados llegan a la cirugía de las EII

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

Molecular healing, our next goal?

Cicatrización molecular: nuestro próximo objetivo?

Molecular effects of IL-23p19 blockade

Transcriptomic profiles in patients with UC receiving filgotinib

Análise do Transcriptoma em doentes com colite ulcerosa tratados com Filgotinib

Molekulare Effekte der IL-23p19-Blockade

Diet & Lifestyle: Keys for the management of IBD!

Diet & Lifestyle: Keys for the management of IBD!